uniQure is a gene therapy biotechnology company with reported revenue growth of 127% year-over-year and analyst consensus implying 40% upside to $34.01, but a cash burn rate of -573% of revenue, a quality score of 1.8 out of 10, and operating margin compression signal that the growth is not yet converting into sustainable financial performance.
Thesis pillars
- Margin Compression Value Trap Signal→Stable
- Exceptional Revenue Growth Rate→Stable
- Substantial Cash Burn Quality Concern→Stable
- +1 more pillar — see the Why tab for full reasoning
uniQure N.V. (QURE) Stock Analysis
Breakout setup · Catalyst-Driven edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $41.99: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 2.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate... Read more
Sell if holding. Engine safety override at $41.99: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 2.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Score 5.7/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, no SEC red flags, news boost analyst cluster(8), earnings proximity 26d clear, semi cycle peak clear, materials cycle peak clear). Fails on clean insider activity. Suitability: speculative.
Recent developments
updated 2026-07-06Recent Developments — uniQure N.V.
Latest news
- NEWS Applied Materials To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday — benzinga Jun 29, 2026 positive
- NEWS HC Wainwright & Co. Maintains Buy on uniQure, Raises Price Target to $80 — benzinga Jun 29, 2026 neutral
- NEWS What's Going On With Capricor Therapeutics Stock On Friday? — benzinga Jun 26, 2026 neutral
- NEWS Mizuho Maintains Outperform on uniQure, Raises Price Target to $68 — benzinga Jun 25, 2026 positive
- NEWS Reported Earlier, uniQure Prices Upsized $225M Public Offering Of 4,945,055 Ordinary Shares At $45.50 Per Share — benzinga Jun 24, 2026 positive
Generated 2026-07-06T04:40:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $41.99: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 2.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Prior stop was $38.88. Score 5.7/10, moderate confidence.
Take-profit target: $56.46 (+35.0% upside). Prior stop was $38.88. Stop-loss: $38.88.
Quality below floor (1.8 < 4.0); Value-trap signals (2/5): Revenue declining (-11.6% YoY), Margin compression (op margin 1.5%).
uniQure N.V. trades at a P/E of N/A (forward -14.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
21 analysts cover QURE with a consensus score of 4.0/5. Average price target: $65.
What does uniQure N.V. do?uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States....
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.